Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
ARKG: Precautionary Measures, But Transformational Objectives Remain Intact
09:23am, Monday, 22'nd Feb 2021
Cathie Wood and her team have shown investors that they have the capability to turn double-digit growth dreams into reality.
Your 2 Best Profit Opportunities in 2021
07:40am, Saturday, 20'th Feb 2021
Infinity Pharmaceuticals is my pick for Stock of the Year. And Shopify is my selection for Stock of the Decade.
Analog Devices, Inc's (ADI) CEO Vince Roche on Q1 2021 Results - Earnings Call Transcript
02:55pm, Wednesday, 17'th Feb 2021
Analog Devices, Inc's (ADI) CEO Vince Roche on Q1 2021 Results - Earnings Call Transcript
Biotech Shares Have Soared Since 2020's Wave of IPOs
09:45am, Wednesday, 17'th Feb 2021
Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.
Roche's Faricimab On Par With Rival Regeneron's Aflibercept In Four Late-Stage Studies In Vision Loss Disorder
12:16pm, Friday, 12'th Feb 2021
Roche Holding's (OCTMKT: RHHBY) bispecific antibody faricimab has matched Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) blockbuster drug, Eylea (aflibercept), in four Phase 3 studies, comparing th
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from four Phase III studies of its investigational bi
Oxford study finds Roche's Actemra reduces Covid deaths
10:51am, Thursday, 11'th Feb 2021
CNBC's Meg Tirrell reports on results from a new Oxford study that shows how Roche's drug Actemra reduces Covid deaths.
Roche's Fourth Quarter Was Ugly, But The Long-Term Quality Remains Sound
11:53am, Wednesday, 10'th Feb 2021
Roche reported a big miss in the fourth quarter, driven by a double-digit miss in Pharmaceuticals, as biosimilars and COVID-19 hit the company hard.
Coherus Deal Signals Pivot to New and Crowded Market
05:00pm, Monday, 08'th Feb 2021
Shares of Redwood City, California-based Coherus BioSciences Inc. (NASDAQ:CHRS) are up about 13% just a week after announcing it has cut a $150 million deal with Chinese drugmaker Junshi Biosciences C
Basel, 8 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to their Elecsys® GDF-15 assay
Roche Working ‘Day and Night' on Covid Treatment Production: CEO
05:28pm, Friday, 05'th Feb 2021
Feb.04 -- Roche Holding AG Chief Executive Officer Severin Schwan said the company is working “day and night” to boost production capacity for the Covid-19 antibody cocktail it's developing with R
Roche Unit Spark Therapeutics' Hemophilia A Gene Therapy Shows Durable Benefit In Early-Stage Study
12:37pm, Friday, 05'th Feb 2021
Spark Therapeutics, a unit of Roche Holdings (OTC: RHHBY), has announced preliminary data from part one of the ongoing Phase 1/2 trial evaluating SPK-8016 in hemophilia A, a genetic deficiency
Roche (RHHBY) 2020 Earnings Down Due to Biosimilars, COVID-19
12:07pm, Friday, 05'th Feb 2021
Roche's (RHHBY) performance in 2020 gets negatively impacted by biosimilar competition and coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.
Preliminary data from four participants who received investigational SPK-8016 at a dose of 5X10 11 vg/kg and have no history of FVIII inhibitors show no serious adverse events and stable and durable f
Roche Holding AG (RHHBY) CEO Severin Schwan on Q4 2020 Results - Earnings Call Transcript
12:15am, Friday, 05'th Feb 2021
Roche Holding AG (RHHBY) CEO Severin Schwan on Q4 2020 Results - Earnings Call Transcript
